Physician profile
David W Smith
NPI 1114902178
$588,338.04
in general payments reported to CMS, 2019-2025
13 companies · $96K in 2025
The $96K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94K · 2020: $48K · 2021: $46K · 2022: $61K · 2023: $130K · 2024: $114K · 2025: $96K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $259K · Consulting Fee: $52K · Travel and Lodging: $21K · Food and Beverage: $7,044 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $259,318.25 |
| Consulting Fee | $52,264.00 |
| Travel and Lodging | $21,290.59 |
| Food and Beverage | $7,044.44 |
| Education | $190.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $370,139.12 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $118,350.39 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $70,029.43 | 2019-2025 | Spravato |
| Axsome Therapeutics, INC. | $26,266.25 | 2022-2024 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,484.69 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $461.65 | 2021-2024 | Caplyta |
| Abbvie INC. | $252.95 | 2021-2023 | Vraylar |
| Indivior INC. | $125.42 | 2019-2022 | |
| Allergan, INC. | $76.75 | 2020 | |
| Tris Pharma INC | $58.69 | 2019 | |
| Alkermes, INC. | $43.58 | 2020-2021 | |
| Almatica Pharma LLC | $26.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.